Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.

Nuche-Berenguer B, Moreno P, Portal-Nuñez S, Dapía S, Esbrit P, Villanueva-Peñacarrillo ML

Regulatory peptides1 Jan 2010Cited by 111 (Europe PMC)

PMID19586609DOI10.1016/j.regpep.2009.06.010PepBankPUB-19586609

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In diabetic and insulin-resistant rats, exendin‑4 further reduced plasma osteocalcin.
In plain wordsIn diabetic and insulin-resistant rats, exendin‑4 further reduced blood osteocalcin.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma osteocalcin
Study
ratn: not reported in source
Type 2 diabetes and insulin resistance
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
osteocalcin (OC) and tartrate-resistant alkaline phosphatase 5b (TRAP5b) were lower; after Ex-4, these turnover markers were further reduced in T2D and IR, while TRAP5b increased in N.
1 context sentence(design, population, supporting numbers)
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660901
02AnimalAnimal study (in vivo)Mechanism
In diabetic and insulin-resistant rats, exendin‑4 further reduced plasma TRAP5b.
In plain wordsIn diabetic and insulin-resistant rats, exendin‑4 further reduced blood TRAP5b.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma TRAP5b
Study
ratn: not reported in source
Type 2 diabetes and insulin resistance
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
osteocalcin (OC) and tartrate-resistant alkaline phosphatase 5b (TRAP5b) were lower; after Ex-4, these turnover markers were further reduced in T2D and IR, while TRAP5b increased in N.
1 context sentence(design, population, supporting numbers)
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660902
03AnimalAnimal study (in vivo)Mechanism
In normal rats, exendin‑4 increased plasma TRAP5b.
In plain wordsIn normal rats, exendin‑4 increased blood TRAP5b.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePlasma TRAP5b
Study
ratn: not reported in source
Normal rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
osteocalcin (OC) and tartrate-resistant alkaline phosphatase 5b (TRAP5b) were lower; after Ex-4, these turnover markers were further reduced in T2D and IR, while TRAP5b increased in N.
1 context sentence(design, population, supporting numbers)
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660903
04AnimalAnimal study (in vivo)Mechanism
In normal, diabetic and insulin-resistant rats, exendin‑4 increased bone osteocalcin mRNA.
In plain wordsIn normal, diabetic and insulin-resistant rats, exendin‑4 increased bone osteocalcin messenger RNA.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBone osteocalcin mRNA
Study
ratn: not reported in source
Normal, diabetic and insulin-resistant rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
Ex-4 increased OC in all groups and OPG in N and IR, reduced RANKL in N and T2D but increased it in IR;
1 context sentence(design, population, supporting numbers)
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660904
05AnimalAnimal study (in vivo)Mechanism
In normal and insulin-resistant rats, exendin‑4 increased bone OPG mRNA.
In plain wordsIn normal and insulin-resistant rats, exendin‑4 increased bone OPG messenger RNA.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBone OPG mRNA
Study
ratn: not reported in source
Normal and insulin-resistant rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
Ex-4 increased OC in all groups and OPG in N and IR, reduced RANKL in N and T2D but increased it in IR;
1 context sentence(design, population, supporting numbers)
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660905
06AnimalAnimal study (in vivo)Mechanism
In normal and diabetic rats, exendin‑4 reduced bone RANKL mRNA.
In plain wordsIn normal and diabetic rats, exendin‑4 reduced bone RANKL messenger RNA.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBone RANKL mRNA
Study
ratn: not reported in source
Normal and type 2 diabetic rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
Ex-4 increased OC in all groups and OPG in N and IR, reduced RANKL in N and T2D but increased it in IR;
1 context sentence(design, population, supporting numbers)
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660906
07AnimalAnimal study (in vivo)Mechanism
In insulin-resistant rats, exendin‑4 increased bone RANKL mRNA.
In plain wordsIn insulin-resistant rats, exendin‑4 increased bone RANKL messenger RNA.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBone RANKL mRNA
Study
ratn: not reported in source
Insulin-resistant rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
Ex-4 increased OC in all groups and OPG in N and IR, reduced RANKL in N and T2D but increased it in IR;
1 context sentence(design, population, supporting numbers)
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660907
08AnimalAnimal study (in vivo)Mechanism
In normal rats, exendin‑4 increased the LRP5/DKK1 mRNA ratio.
In plain wordsIn normal rats, exendin‑4 increased the LRP5/DKK1 messenger RNA ratio.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseLRP5/DKK1 mRNA ratio
Study
ratn: not reported in source
Normal rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
after Ex-4, both ratios augmented in N, and that of LRP5/DKK1 tended to normalize in T2D and IR.
1 context sentence(design, population, supporting numbers)
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660908
09AnimalAnimal study (in vivo)Mechanism
In normal rats, exendin‑4 increased the LRP5/SOST mRNA ratio.
In plain wordsIn normal rats, exendin‑4 increased the LRP5/SOST messenger RNA ratio.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseLRP5/SOST mRNA ratio
Study
ratn: not reported in source
Normal rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
after Ex-4, both ratios augmented in N, and that of LRP5/DKK1 tended to normalize in T2D and IR.
1 context sentence(design, population, supporting numbers)
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660909
10AnimalAnimal study (in vivo)Mechanism
In diabetic rats, exendin‑4 tended to normalize the reduced LRP5/DKK1 mRNA ratio.
In plain wordsIn diabetic rats, exendin‑4 tended to normalize the reduced LRP5/DKK1 messenger RNA ratio.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseLRP5/DKK1 mRNA ratio
Study
ratn: not reported in source
Type 2 diabetic rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
after Ex-4, both ratios augmented in N, and that of LRP5/DKK1 tended to normalize in T2D and IR.
2 context sentences(design, population, supporting numbers)
Summary · context
the LRP5/DKK1 and LRP5/SOST mRNA ratios were similarly decreased in T2D, but in IR, the latter ratio was reduced while the former was increased;
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660910
11AnimalAnimal study (in vivo)Mechanism
In insulin-resistant rats, exendin‑4 tended to normalize the increased LRP5/DKK1 mRNA ratio.
In plain wordsIn insulin-resistant rats, exendin‑4 tended to normalize the increased LRP5/DKK1 messenger RNA ratio.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseLRP5/DKK1 mRNA ratio
Study
ratn: not reported in source
Insulin-resistant rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · osmotic pump · 3 daysAs given in this study (rat).
Source sentences
Summary
after Ex-4, both ratios augmented in N, and that of LRP5/DKK1 tended to normalize in T2D and IR.
2 context sentences(design, population, supporting numbers)
Summary · context
the LRP5/DKK1 and LRP5/SOST mRNA ratios were similarly decreased in T2D, but in IR, the latter ratio was reduced while the former was increased;
Summary · context
We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway.
Report a problemFND-1958660911

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.

Summary

Results from this study11

Version history

Subjects

Publication types

MeSH terms